CODEXIS, INC. (CDXS)
NASDAQ · Chemicals · Industrial Organic Chemicals
- Price
- $1.38
- Day
- -0.72%
- Market cap
- $151.12M
Close 2026-09-23.
The company
COMPANY OVERVIEW We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by using o ur proprietary CodeEvolver ® directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions. They can be precisely engineered and optimized for specific functions, and to have particular characteristics, such as an ability to survive environments in which natural enzymes cannot, or to perform (bio)chemical transformations that are different than those for which they naturally evolved. We employ our technology and expertise to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key areas: our ECO synthesis manufacturing platform and our small molecule pharma biocatalysis business.
From Item 1: COMPANY OVERVIEW.
By product & service
- Research and Development Revenue — 63%
- Product — 37%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- Opaleye Management Inc. — $15.33M
- Aberdeen Group plc — $15.3M
- MILLENNIUM MANAGEMENT LLC — $12.54M
- BlackRock, Inc. — $9.15M
- Telemark Asset Management, LLC — $8.69M
- AMERIPRISE FINANCIAL INC — $8.61M
- Nantahala Capital Management, LLC — $8.19M
- Nantahala Capital Management, LLC — $8.19M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- De Vre Raymond (Director) sold 2,605 shares at $2.37 on 2026-06-11
- Lutz Stefan (Chief Scientific Officer) sold 5,862 shares at $1.13 on 2026-02-24
- Lutz Stefan (Chief Scientific Officer) sold 2,492 shares at $1.31 on 2026-02-06
- Erbez Georgia (See Remarks) sold 3,826 shares at $1.31 on 2026-02-06
- MOORE ALISON (President and CEO) sold 3,826 shares at $1.31 on 2026-02-06
- Lutz Stefan (CSO) sold 4,685 shares at $1.70 on 2026-01-07
Recent filings
- SCHEDULE 13G/A — 2026-08-13
- 10-Q — 2026-08-11
- 8-K — 2026-08-11
- SCHEDULE 13G — 2026-07-29
- 8-K — 2026-07-27
- 424B5 — 2026-07-24
- 424B5 — 2026-07-23
- 8-K — 2026-07-23
- SCHEDULE 13G/A — 2026-07-20
- 8-K — 2026-06-22